Floatz logo

Conatumumab

Locally Advanced

Amgenmonoclonal_antibodyPhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Locally Advanced cohort.

Asset / SponsorPhaseRating
Irinotecan
Salah Azaïz Cancer Institute
Phase 3BB
(+)-VINCRISTINE
Amgen
Phase 3BB
Bms-907351
Centre Francois Baclesse
Phase 4BB
Epirubicin
PMV Pharmaceuticals, Inc
Phase 2B
Nivolumab
Centre Francois Baclesse
Phase 4B

View all 26 →

Same molecule, other indications

Conatumumab is also rated in:

colorectal cancerDormant
B
Indicative ·
58 / 100
View asset →
metastatic malignant neoplasmDormant
B
Indicative ·
57 / 100
View asset →
sarcomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →